BCR-ABL1 is an abnormal gene present in certain types of leukemia. Genetic testing for BCR-ABL1 helps doctors diagnose these cancers and assess their response to treatment. If you or someone you know ...
Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients
The alternative text for this image may have been generated using AI. Freshly collected or frozen bone marrow or peripheral blood samples were obtained from the patients in accordance to the ...
Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML. Our ...
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
Measuring biochemical recurrence (BCR) as a surrogate marker produces unreliable results as a primary end point for overall survival of patients with localized prostate cancer, a study found. In a ...
Biochemical recurrence endpoints did not reliably predict overall survival in prostate cancer trials. Treatments that reduce the risk for biochemical recurrence (BCR) do not necessarily improve ...
FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...
BCR Announces Strategic Partnership to Bring Leading Belt Dryer Brand SEVAR to North American Market
JACKSONVILLE, Fla.--(BUSINESS WIRE)--BCR Inc, a leading provider of proven biosolids and process treatment technology solutions, announced today a strategic partnership with leading Germany-based belt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results